J Gynecol Oncol.  2011 Dec;22(4):239-243. 10.3802/jgo.2011.22.4.239.

Survival outcome of women with synchronous cancers of endometrium and ovary: a 10 year retrospective cohort study

• Lim YK
• Padma R
• Foo L
• Chia YN
• Yam P
• Chia J
• Khoo-Tan H
• Yap SP
• Yeo R

• KMID: 2173625
• DOI: http://doi.org/10.3802/jgo.2011.22.4.239

Abstract

OBJECTIVE
Synchronous occurrence of endometrial and ovarian tumors is uncommon, and they affect less than 10% of women with endometrial or ovarian cancers. The aim of this study is to describe the epidemiological and clinical factors; and survival outcomes of women with these cancers.
METHODS
This is a retrospective cohort study in a large tertiary institution in Singapore. The sample consists of women with endometrial and epithelial ovarian cancers followed up over a period of 10 years from 2000 to 2009. The epidemiological and clinical factors include age at diagnosis, histology types, grade and stage of disease.
RESULTS
A total of 75 patients with synchronous ovarian and endometrial cancers were identified. However, only 46 patients met the inclusion criteria. The median follow-up was 74 months. The incidence rate for synchronous cancer is 8.7% of all epithelial ovarian cancers and 4.9% of all endometrial cancers diagnosed over this time frame. Mean age at diagnosis was 47.3 years old. The most common presenting symptom was abnormal uterine bleeding (36.9%) and 73.9% had endometrioid histology for both endometrial and ovarian cancers. The majority of the women (78%) presented were at early stages of 1 and 2. There were 6 (13.6%) cases of recurrence and the 5 year cumulative survival rate was at 84%.
CONCLUSION
In our cohort, we found that majority of women afflicted with synchronous cancer of the endometrium and ovary were younger at age of diagnosis, had early stage of cancer and good survival.

Keyword

Endometrial cancer; Ovarian cancer; Synchronous cancer

MeSH Terms

Benzeneacetamides
Cohort Studies
Endometrial Neoplasms
Endometrium
Female
Follow-Up Studies
Humans
Incidence
Ovarian Neoplasms
Ovary
Piperidones
Recurrence
Retrospective Studies
Singapore
Survival Rate
Uterine Hemorrhage
Benzeneacetamides
Piperidones

Figure

• 

  Fig. 1 Kaplan-Meier survival analysis (n=46). CI, confidence interval.

Reference

1. Zaino R, Whitney C, Brady MF, DeGeest K, Burger RA, Buller RE. Simultaneously detected endometrial and ovarian carcinomas: a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecol Oncol. 2001. 83:355–362.

2. Woodruff JD, Solomon D, Sullivant H. Multifocal disease in the upper genital canal. Obstet Gynecol. 1985. 65:695–698.

3. Eisner RF, Nieberg RK, Berek JS. Synchronous primary neoplasms of the female reproductive tract. Gynecol Oncol. 1989. 33:335–339.

4. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament. Atlas of tumor pathology. 1998. Bethesda, MD: Washington Armed Forces Institute of Pathology.

5. Soliman PT, Slomovitz BM, Broaddus RR, Sun CC, Oh JC, Eifel PJ, et al. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol. 2004. 94:456–462.

6. Caldarella A, Crocetti E, Taddei GL, Paci E. Coexisting endometrial and ovarian carcinomas: a retrospective clinicopathological study. Pathol Res Pract. 2008. 204:643–648.

7. Gemer O, Bergman M, Segal S. Ovarian metastasis in women with clinical stage I endometrial carcinoma. Acta Obstet Gynecol Scand. 2004. 83:208–210.

8. Ulbright TM, Roth LM. Metastatic and independent cancers of the endometrium and ovary: a clinicopathologic study of 34 cases. Hum Pathol. 1985. 16:28–34.

9. Shenson DL, Gallion HH, Powell DE, Pieretti M. Loss of heterozygosity and genomic instability in synchronous endometrioid tumors of the ovary and endometrium. Cancer. 1995. 76:650–657.

10. Fujita M, Enomoto T, Wada H, Inoue M, Okudaira Y, Shroyer KR. Application of clonal analysis. Differential diagnosis for synchronous primary ovarian and endometrial cancers and metastatic cancer. Am J Clin Pathol. 1996. 105:350–359.

11. Lin WM, Forgacs E, Warshal DP, Yeh IT, Martin JS, Ashfaq R, et al. Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas. Clin Cancer Res. 1998. 4:2577–2583.

12. Ricci R, Komminoth P, Bannwart F, Torhorst J, Wight E, Heitz PU, et al. PTEN as a molecular marker to distinguish metastatic from primary synchronous endometrioid carcinomas of the ovary and uterus. Diagn Mol Pathol. 2003. 12:71–78.

13. Moreno-Bueno G, Gamallo C, Perez-Gallego L, de Mora JC, Suarez A, Palacios J. Beta-Catenin expression pattern, betacatenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol. 2001. 10:116–122.

14. Kaneki E, Oda Y, Ohishi Y, Tamiya S, Oda S, Hirakawa T, et al. Frequent microsatellite instability in synchronous ovarian and endometrial adenocarcinoma and its usefulness for differential diagnosis. Hum Pathol. 2004. 35:1484–1493.

15. Shannon C, Kirk J, Barnetson R, Evans J, Schnitzler M, Quinn M, et al. Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium. Clin Cancer Res. 2003. 9:1387–1392.

16. Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol. 2008. 9:1191–1197.

17. Eifel P, Hendrickson M, Ross J, Ballon S, Martinez A, Kempson R. Simultaneous presentation of carcinoma involving the ovary and the uterine corpus. Cancer. 1982. 50:163–170.

18. Chiang YC, Chen CA, Huang CY, Hsieh CY, Cheng WF. Synchronous primary cancers of the endometrium and ovary. Int J Gynecol Cancer. 2008. 18:159–164.